Recent 8-K filings for GOSS

• July 14, 2026, 8:39 PM ET other material materiality 0.65 neutral item 5.02item 5.03item 5.07item 9.01

  Gossamer Bio stockholders approve 4B authorized shares, new incentive plan, and note/warrant issuance

  Stockholders approved charter amendment increasing authorized common shares from 700M to 4B.

• July 1, 2026, 9:01 AM ET other material materiality 0.35 neutral item 7.01item 9.01

  Gossamer Bio sets conversion price ~$0.19/sh for 7.50% notes; warrant strike $0.34

  Initial conversion rate: 5,347.5936 shares per $1,000 principal of 2030 Convertible Notes, equivalent to ~$0.19 conversion price.

• June 17, 2026, 8:01 AM ET debt materiality 0.70 positive item 7.01item 9.01

  Gossamer Bio completes exchange of 94.5% of 2027 notes; $18.9M remain outstanding

  $181.1M principal (94.5%) of 5% 2027 notes tendered; exchanged for new 7.5% 2030 notes and equity.

• June 4, 2026, 7:28 PM ET debt materiality 0.85 neutral item 1.01item 1.02item 2.03item 3.02item 7.01item 9.01 ◈ Equity Issuances ×4◈ Material Agreements ×2◈ Debt Financings

  Gossamer Bio exchanges 90.5% of 5% notes for new 7.5% notes, stock, and warrants

  $181M of 5% Convertible Senior Notes due 2027 tendered and cancelled (90.5% of outstanding).

• June 4, 2026, 5:34 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Gossamer Bio shareholders re-elect directors, ratify EY, approve say-on-pay

  Faheem Hasnain re-elected as Class II director with 92.3M for, 26.7M withheld, 45.5M broker non-votes.

• June 2, 2026, 8:00 AM ET debt materiality 0.65 neutral item 8.01item 9.01

  Gossamer Bio extends early tender deadline for exchange offer; $181M of notes tendered

  Early tender deadline extended to 5:00 p.m. ET on June 2, 2026; early settlement expected June 4, 2026.

• May 18, 2026, 7:06 AM ET debt materiality 0.85 neutral item 1.01item 2.02item 5.02item 7.01item 8.01item 9.01 ◈ Earnings Releases◈ Material Agreements

  Gossamer Bio launches exchange offer for 5.00% notes; holders of 75.2% support

  Exchange Offer: up to $72M new 7.50% Convertible Secured Notes due 2030, plus up to 317.6M common shares and 150M Purchase Warrants.

• April 9, 2026, 7:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Gossamer Bio receives Nasdaq bid price deficiency notice; 180 days to cure

  Nasdaq notified Gossamer on April 8, 2026 that stock bid price <$1.00 for 30 consecutive business days (Feb 24 – Apr 7, 2026).

• March 17, 2026, 7:59 PM ET other material materiality 0.90 negative item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint

  PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).

• February 23, 2026, 6:59 PM ET other material materiality 0.85 neutral item 8.01item 9.01

  Gossamer Bio Phase 3 PROSERA trial misses primary endpoint, seralutinib shows signals in high-risk PAH

  Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).

• November 5, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026

  Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.

• September 25, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 ◈ Equity Issuances ×3

  Gossamer Bio issues 2.5M shares for option to acquire Respira Therapeutics

  Issued 2,500,000 shares to Prana Bio on Sept 24, 2025 as consideration for option to acquire Respira via merger.

• August 5, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026

  Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.

• June 25, 2025, 7:59 PM ET other materiality 0.25 neutral item 5.02item 5.07

  Stockholders re-elect three Class I directors, approve amended incentive plan

  Class I directors re-elected: Thomas Daniel, Sandra Milligan, Steven Nathan.

• June 16, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)

  Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.

• May 15, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M

  Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.

• March 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025

  Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.

• February 19, 2025, 6:59 PM ET regulatory materiality 0.55 positive item 8.01

  Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed.

  Received Nasdaq notice on Feb 19, 2025 confirming regained compliance with minimum bid price rule.

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027

  Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.

• September 13, 2024, 7:59 PM ET other material materiality 0.70 negative item 3.01

  Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025

  Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.

• August 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track

  Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.

• July 18, 2024, 7:59 PM ET regulatory materiality 0.55 positive item 8.01

  Gossamer Bio regains Nasdaq minimum bid price compliance; listing matter closed

  Received Nasdaq letter on July 18, 2024 confirming regained compliance with minimum bid price rule.

• June 10, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Gossamer Bio reports annual meeting results; all proposals approved

  Skye Drynan and John Quisel re-elected as Class II directors for three-year terms.

• May 24, 2024, 7:59 PM ET other material materiality 0.60 negative item 3.01

  Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024

  Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.

• May 7, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib

  Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.

• May 6, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 1.02item 3.02item 8.01item 9.01 ◈ Material Agreements

  Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront

  Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.

• March 12, 2024, 7:59 PM ET leadership materiality 0.60 positive item 5.02item 9.01 ◈ executive_change ×2

  Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board

  Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.

• March 5, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026

  First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.

• March 4, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed

  Received Nasdaq letter on March 4, 2024 confirming compliance with minimum bid price rule.

• November 29, 2023, 6:59 PM ET leadership materiality 0.40 positive item 5.02item 9.01 ◈ executive_change

  John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck

  Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.

• November 27, 2023, 6:59 PM ET other material materiality 0.50 neutral item 5.02item 5.03item 9.01 ◈ Governance Changes

  Gossamer Bio adopts 2023 inducement plan reserving 6.76M shares for new hires and amends bylaws

  Board approved 2023 Inducement Plan with 6,762,279 common shares reserved for grants to new employees as material inducement to hire.

• November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead

  Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).

• October 20, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Gossamer Bio receives Nasdaq notice for non-compliance with $1.00 minimum bid price; 180-day cure period.

  Nasdaq notified Gossamer Bio on Oct 19, 2023 that its common stock had a closing bid price below $1.00 for 30 consecutive business days.

• September 7, 2023, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change

  Gossamer Bio board member Kristina Burow resigns effective September 6, 2023

  Kristina Burow resigned from the Board due to other board commitments, not due to any disagreement with the company.

• August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement

  Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.

• July 20, 2023, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design

  Announced interim data from open-label extension of seralutinib in PAH patients.

• July 20, 2023, 7:59 PM ET other material materiality 0.85 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design

  Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.

• June 9, 2023, 7:59 PM ET other material materiality 0.25 neutral item 5.03item 5.07item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

  Gossamer Bio shareholders approve officer liability amendment, re-elect directors at annual meeting

  Amendment to eliminate officer liability for monetary damages passed with 55.97M for, 2.92M against, effective June 8, 2023.

• May 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH

  Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.

• April 3, 2023, 7:59 PM ET regulatory materiality 0.90 negative item 8.01

  Gossamer Bio discontinues GB5121 after FDA partial clinical hold; SAEs included fatal hemorrhage

  FDA placed partial clinical hold on all GB5121 trials after atrial fibrillation, sudden death, and fatal intracranial hemorrhage in STAR-CNS study.

• March 17, 2023, 7:59 PM ET other material materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3

  Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.

• December 6, 2022, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH

  Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).

• November 3, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec

  Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.

• August 9, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022

  Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.

• July 13, 2022, 7:59 PM ET other material materiality 0.70 positive item 1.01item 3.02item 7.01item 9.01

  Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share

  Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.

• June 10, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Gossamer Bio stockholders re-elect three Class I directors, ratify auditor, approve say-on-pay

  Kristina Burow, Thomas Daniel, and Sandra Milligan re-elected as Class I directors with over 89% of votes cast (excluding broker non-votes).

• May 10, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M

  Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.

• April 25, 2022, 7:59 PM ET other material materiality 0.85 negative item 2.02item 8.01

  Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated

  Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).

• March 3, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022

  Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).

• November 8, 2021, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022

  Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

13 positive 8 negative 29 neutral

source · GOSS on sec.gov